Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ: AUPH )

8.260 +0.150 (+1.85%)
Streaming Delayed Price Updated: 10:17 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
Aurinia Pharma Stock Showing A Potential Reversal Pattern: 4 Key Levels To Watch
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) was trending Tuesday afternoon poss... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 33 companies set new 52-week lows. Highlights: The largest company by market cap to set a new 52-week low was iQIYI (NASDAQ:IQ).... 
Via Benzinga
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... 
Via Benzinga
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Heavy News Day - Cheats
US job losses were up 744,000 vs a forecast of 694,000. 
Via Talk Markets
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Aurinia's Lupkynis Shows Treatment Benefit In Lupus Nephritis, Additional Efficacy Data Shows
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus... 
Via Benzinga
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Stock Has Great Potential, but It’s Not a Buy Right Now
AUPH stock still has to prove its Lupus drug can sell and its price and the competition make that an unclear proposition. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.